For patients with heart failure and reduced ejection fraction (HFrEF),angiotensin receptor–neprilysin inhibitors (ARNIs) such as sacubitril/valsartanhave demonstrated superiority over ACE inhibitors in reducing cardiovascularmortality and hospitalizations, as shown in the PARADIGM-HF trial [35]. This evidence concerns the gene ACE and heart failure.